Bender Robert & Associates Invests $475,000 in Urogen Pharma $URGN

Key Points

• Bender Robert & Associates invested approximately $475,000 in Urogen Pharma, acquiring 34,701 shares, representing 0.08% ownership at the end of the last reporting period.
• Multiple large investors have significantly increased their stakes in Urogen Pharma, with CWM LLC raising its position by over 6,000% in the first quarter alone.
• Urogen Pharma's stock price has fluctuated between a 52-week low of $3.42 and a high of $21.71, currently trading around $16.42 after recently missing earnings expectations.

Bender Robert & Associates bought a new position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 34,701 shares of the company's stock, valued at approximately $475,000. Bender Robert & Associates owned 0.08% of Urogen Pharma at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. CWM LLC raised its stake in shares of Urogen Pharma by 6,047.1% during the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock worth $58,000 after buying an additional 5,140 shares during the period. GAMMA Investing LLC increased its position in shares of Urogen Pharma by 6,908.4% during the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock worth $83,000 after purchasing an additional 7,392 shares in the last quarter. Partners Capital Investment Group LLP purchased a new stake in shares of Urogen Pharma during the first quarter worth approximately $170,000. Persistent Asset Partners Ltd purchased a new stake in shares of Urogen Pharma during the first quarter worth approximately $194,000. Finally, Pale Fire Capital SE increased its position in shares of Urogen Pharma by 67.1% during the first quarter. Pale Fire Capital SE now owns 20,893 shares of the company's stock worth $231,000 after purchasing an additional 8,393 shares in the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently commented on URGN shares. Oppenheimer set a $31.00 price target on Urogen Pharma and gave the stock a "buy" rating in a research report on Friday, June 13th. The Goldman Sachs Group set a $16.00 price target on Urogen Pharma and gave the stock a "neutral" rating in a report on Friday, June 13th. Piper Sandler initiated coverage on Urogen Pharma in a research note on Monday, August 18th. They set an "overweight" rating and a $36.00 target price on the stock. Guggenheim reaffirmed a "buy" rating and issued a $30.00 price target (up previously from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. Finally, Wall Street Zen raised Urogen Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, September 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $32.00.

Insider Buying and Selling at Urogen Pharma

In other Urogen Pharma news, CFO Chris Degnan sold 2,203 shares of Urogen Pharma stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $16.85, for a total value of $37,120.55. Following the transaction, the chief financial officer directly owned 2,280 shares in the company, valued at approximately $38,418. This trade represents a 49.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $17.69, for a total value of $176,900.00. Following the completion of the transaction, the insider owned 148,229 shares in the company, valued at $2,622,171.01. This trade represents a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 27,265 shares of company stock worth $502,236. 4.70% of the stock is currently owned by insiders.

Urogen Pharma Stock Down 5.3%

NASDAQ:URGN opened at $16.42 on Friday. The stock's 50 day moving average price is $18.83 and its 200 day moving average price is $13.81. The company has a market capitalization of $759.65 million, a PE ratio of -4.95 and a beta of 1.00. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $21.71.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.23). Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. The company had revenue of $24.22 million during the quarter, compared to analysts' expectations of $23.06 million. As a group, sell-side analysts anticipate that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Urogen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.